Preliminary results of targeted prostate ‐specific membrane antigen imaging in evaluating the efficacy of a novel hormone agent in metastatic castration‐resistant prostate cancer
We found it very accurate to evaluate the effect of abiraterone on prostate cancer using PSMA molecular imaging. PSMA imaging is expected to replace traditional imaging in prostate diagnosis and treatment AbstractTo investigate the feasibility and effectiveness of prostate ‐specific membrane antigen (PSMA) imaging to make response assessment regarding novel hormone treatment and to predict the outcomes for metastatic castration‐resistant prostate cancer (mCRPC) patients. This retrospective study enrolled 68 mCRPC patients who had daily received a novel hormone age nt named abiraterone. Tc‐99m PSMA single‐photon emission computed tomography (SPECT/CT) was performed at the baseline (SPECT/CT1) and after 3‐6 months of treatment (SPECT/CT2). The treatment response was determined by visual analysis based on molecular imaging PSMA (miPSMA) scores framework a nd was compared with conventional biochemical analysis. We chose either the hottest lesion (target A) or five of the hottest lesions (target B) to calculate the tumor/background ratio (TBR) and the maximum standardized uptake value (SUVmax) and compared their performances in predicting progression‐ free survival (PFS). Changes in PSMA expression between SPECT/CT1 and SPECT/CT2 were well associated with the results of the visual analysis. The TBR and the SUVmax of both targets were significantly associated with the baseline serum PSA level (P < .0001). The biochemical and radiological responses were concordant...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Chang Liu,
Yao Zhu,
Hengchuan Su,
Xiaoping Xu,
Yingjian Zhang,
Shaoli Song,
Beihe Wang,
Dingwei Ye,
Silong Hu Tags: ORIGINAL RESEARCH Source Type: research